Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc

Criteria

Inclusion Criteria:

• Chronic kidney disease patients on hemodialysis

• Hyperphosphatemia

• Written informed consent

Exclusion Criteria:

• Patients with gastrointestinal surgery or enterectomy

• Severe cardiac disease patients

• Patients with severe constipation or diarrhea

• Patients with a complication of malignant tumors

• Patients with uncontrolled hypertension

• Patients treated with parathyroid intervention